Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis
Conclusions:
The JAK inhibitors, in particular tofacitinib, are a new class of orally administered drugs effective for the treatment of UC. However, more studies are needed to ascertain the safety of tofacitinib in the long term and whether other compounds of this class may be equally effective.
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: CLINICAL REVIEWS Source Type: research
More News: Corticosteroid Therapy | Gastroenterology | Inflammatory Bowel Disease | Study | Ulcerative Colitis